Urinary Tract InfectionsNCT02249273
Diagnostic Tools in Patients With a Suspected Urinary Tract Infection in Primary Care
An observational study of Urinary Tract Infections, run by University of Copenhagen at 1 site in Denmark.
Trial summary
Background: Inappropriate use of antibiotics is one of the main causes for the increase of antibiotic resistance strains. In Denmark general practice accounts for 90% of all prescribed antibiotics and one of the most common reasons for prescribing antibiotics is the suspicion of a urinary tract infection (UTI). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Urinary Tract Infections
- What is being tested?
- Diagnostic approaches
- How many people
- 500 participants
- Where
- 1 siteDenmark
- Study dates
- Dec 2014to Dec 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients >0 18 years old attending primary care services during offcie hours with a suspected urinary tract infection
Who may be able to join
- Suspected Urinary tract infection
- > 18 years of age
- Patient consulting during office hours.
Who cannot join
- Patients currently taking antibiotics
- Inability to complete a diary and send two urine samples during the time of the study
- Patients with a urinary catheter as they have a closer follow-up between first and secondary care.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Diagnostic Process in Patients With a Suspected Urinary Trcat Infection in Danish Primary Care: Impact on Appropriate Use of Antibiotics and Patient's Recovery.
Background: Inappropriate use of antibiotics is one of the main causes for the increase of antibiotic resistance strains. In Denmark general practice accounts for 90% of all prescribed antibiotics and one of the most common reasons for prescribing antibiotics is the suspicion of a urinary tract infection (UTI). The use of point-of-care test is meant to decrease the uncertainty about the bacterial origin of the symptoms; however, there is a paucity of knowledge about the validity of the different diagnostic approaches, thus impacting on the proper use of antibiotics.
Objective: To assess the diagnostic validity of different diagnostic approaches in patients with a suspected urinary tract infection and assess the impact on appropriate use of antibiotics.
Read more
Methods: 70 practices at the capital region will consecutively include 15-20 patients. The inclusion criteria of the patients comprise: a) Suspected Urinary tract infection, b) > 18 years of age, c) patient consulting during office hours. Data at patient and GP level will be gathered.
16 diagnostic approaches will be compared and proper use of antibiotics will be assessed as a two-step process. The first step is the decision made during the consultation and the second step is the decision made after the consultation. Sensitivity, specificity and predictive values will be measure for each diagnostic approach using urine culture as a gold standard. The impact on proper use of antibiotics will be assessed in a hierarchical multivariable logistic model.
Read the detailed description
Background
The latest report from the Staten Serum Institute (SSI)1 showed that primary health care in Denmark represents 90% of all prescribed defined daily dose(DDD) of antibiotics, and that a growing consumption of antibiotics is running alongside increasing resistance to E. coli, specifically ESBL-producing E. coli (Extended Spectrum Beta Lactamase Producing E. coli) .
The main cause of E. coli infection at primary care level is a Urinary Tract Infection (UTI) which is one of the most frequent reasons for consultation in general practice in Denmark. Interestingly, there is no consensus yet about the most effective diagnostic approach to identify those patients that will benefit from antibiotic therapy.
Currently in Denmark, a wide variety of diagnostic approaches can be identified in primary care settings (i.e. only history taking, dipsticks, microscopy, culture and susceptibility testing in practice). Nonetheless, there is not conclusive evidence yet about the diagnostic validity of all these approaches and the association with appropriate prescription of antibiotics(i.e. correct decision to prescribe and correct choice of antibiotics reflecting the bacterial cause and resistance) and impact on patients' clinical and microbiological cure.
For example, some studies that only include uncomplicated UTIs have shown that symptoms alone have a very low predictive value leading to overuse of antibiotics2,3. However, Richards et al after comparing the response to antibiotics of women with symptoms of UTI and a negative dipstick test result, concluded that empirical antibiotic use guided only by symptoms was a reasonable option4.
Furthermore, microscopy and more recent diagnostic tools such as a culture performed in primary care settings have not been included in the latest pragmatic validation studies5,6. Phase-contrast microscopy is widely used in primary care in Denmark, although the very few studies on the subject show wide variation in sensitivity (60-100%) and specificity (49-100%) of urine microscopy to predict significant bacteriuria.
Besides susceptibility testing at primary care level is only done in Denmark and the quality control of the performance of these tests differs across the country. MIKAP (the Danish agency in charge of the surveillance of the quality of the microbiological tests performed in general practices) supervises only some Danish Regions and has not authority on the quality control of the tests carried out in the capital region.
In order to curb the development of resistance bacteria strains in patients with urinary tract symptoms and infections, we need to increase our knowledge of the validity of the different diagnostic approaches and its impact on proper use of antibiotics and recovery across the heterogeneous group of patients seeking health care in primary care.
Objectives
The central research question will be answered throughout the following specific objectives:
- To assess the diagnostic validity (i.e. sensitivity and specificity, positive and negative predictive value) of different diagnostic approaches in ruling in or ruling out a UTI in different sub-population groups in general practice.
- To describe the impact of different diagnostic approaches on the appropriateness of antibiotic therapy (i.e. decision to prescribe and choice of antibiotic).
- To describe the impact of different diagnostic approaches on clinical and microbiological cure.
- To measure the prevalence of ESBL-resistant E.coli in patients with urinary tract symptoms in general practice.
Materials and Methods:
Design and setting: Prospective observational study with comparison of different diagnostic approaches to gold standard in general practice.
Data Collection: Before the index consultation, the participating GPs will be asked to complete a background questionnaire about experience, organization of the service and access to different diagnostic tools.
The day of the index consultation, when the GP types the ICPC code for dysuria (U01) or frequency (U02), as a main motive of consultation, a pop-up will automatically appear with a questionnaire about the anamnesis, diagnostic approach, treatment and other relevant decisions made during the consultation; this questionnaire will be directly linked to DAK-E/DAMD database (Danish General Practice database aimed at improving quality in the delivery of primary medical care services). Afterwards, the patient will also be asked to provide a urine sample which will be sent to the Staten's Serum Institute (SSI) for culture, which will be used as the reference gold standard.
The following 14 days after the index consultation, the patients will complete a symptom diary (attached). They will be asked to rate some symptoms each day until recovery (or for 7 days if symptoms are ongoing) on a 3 point scale from "nothing " to "a lot". After 14 days patients will have to send a control urine sample. Patients with a persistently positive culture will be followed up after 1and 3 months.
Further information about patient background regarding co-morbidities, previous hospitalizations, and previous use of antibiotics will be gathered from national registers such as The Danish national patients register and The Danish national prescription register.
Biobank: 10 µl of urine will be stored following the safety and hygiene procedures of the Staten's Serum Institute microbiological laboratory only for those urine samples positive for ESBL-producing E. coli. After detection of a positive resistant strain, the samples will be anonymized and stored for a period of 2 years after completion of the current study. We plan to carry out further microbiological analysis of the resistant bacteria in collaboration with experts in proteonomics and genomics within the bigger UC-CARE projects. The collection of the urine sample does not represent any risk for the patients as it follows the normal procedure in general practice, it means, the patients is requested to collect a random urine sample in a plastic cup at the practice facility and 14 days after at home.
Data management: All data will be entered into a database which will be linked to different national registers to obtain detailed data about background information at patient level. Data will be screened for data entry errors and extreme values using tables, plots and specific commands of the SAS 9.03.
Variables: considering the multidimensional and multivariable models that will have to be constructed in order to accurately answer the objectives, the following variables with the corresponding data source will be included:
Patient level
Patients' demographics (gender, age), dysuria, frequency, supra-pubic pressure, polyuria, Fever (>38oC), trembling, urine offensive smell, gynecological complaints (vaginal discharge, pruritus), low back pain, blood in urine. Number of days since first symptom started. Diagnostic test:, diagnose, treatment, severity of symptoms, bothersomeness, impact on daily activities. Previous hospitalization within the last year: diagnosis, discharge date. Consumption of antibiotics within the last year.
GP level Number of consultations during office hours due to dysuria and/or frequency as a main motive of consultation, GPs' demographics, number of patients in the GPs' list, point-of-care test for urine examination: type of point-of-care tests available in the practice, brand and technical specifications for each test. Attendance to courses about performance of the tests.
Statistical analysis: Data will be analyzed using SAS 9.03. A comparison of proportions will be performed using the chi-square test. For the first two objectives, the result of the urine culture will be used as the gold standard, a cut-off value of >=103cfu/ml, or pure growth of E.coli, and > 10 4 for more unusual organisms or mixed growth will be used to define a positive culture,and we will calculate sensitivity, specificity, negative predictive value and positive predictive value for each diagnostic approach against the gold standard.
Regarding the third objective prescription of antibiotics and choice of the right antibiotic will be operationalized as binary dependent variables in a logistic regression model, while for the last two objectives number of days until symptomatic and microbiological cure will be analyzed as continuous dependent variables in a multiple linear regression model. Depending on the number of cases included in the one month and three months follow-up of microbiological cure, a Poisson regression model will be developed.
The propensity score matching technic will be employed to adjust for pre-test imbalances in the different groups of treatment approaches in order to produce unbiased estimates of the tests effect on the main outcomes and create participant characteristic balance among the groups.
Sample calculation Different samples sizes will be needed to compare proper use of antibiotics between the 16 diagnostic profiles. Due to the observational design of the study, we do not know yet with certainty the distribution of the diagnostic profiles, so at least there are two samples sized we are aiming at. The first one aims to see a clinically relevant 10% difference in proper use of antibiotics when comparing the diagnostic profiles that affect the decision during the consultation versus the diagnostic profiles that affect the decision after the consultation.
The assumptions are: a) the 4 diagnostic profiles that influence the decision during the consultation are use in 60% of the patients, b) the correct decision is taken in 60% of the patients in this group, while c) the correct decision during the consultation is taken only in 40% of the patients in which any of the remaining 12 diagnostic profiles are performed. We will need 60 practices recruiting 15 patients each (n=900). Intra-class correlation =0.2, α=0.05 and β=0.2.
The second sample size relates to the detection of a prevalence of ESBL-producing E. Coli between 0 to 6% in patients with a suspected UTI in primary care. Our assumptions for the sample calculation are as follows: a) 60% of patients with symptoms do not have a positive culture, b) 80% of the patients with a positive culture are infected with a E.Coli strain. Therefore, we need 1500 patients with a suspected UTI attending primary care to detect a prevalence of ESBL-resistant E.coli between 0 to 6% with a 95% confidence interval.
Ethics
The study does not represent any risk for the patients due to the observational design. It means the diagnostic process and the treatment will be register as it is done in every day practice. Participation in the study implies for the patient that they have to fill in a diary about symptoms for 7 days and they should be willing to be contacted 3 days and 14 days after by the personnel from the practice to know whether they have filled in the diary, sent it to the research unit and sent the second sample to the microbiological department. Consequently, the course of the symptoms/disease is not affected by the fact of participating or not in the study.
All the personnel at each practice will be informed about the study, so as soon as the patient contacts the practice due to the symptoms listed at the inclusion criteria section, they will receive the first information about the study.
The first contact person (i.e. secretary, nurse, general practitioner) will ask the patient whether they are interested in participating in a project that aims to improve the management of patients with a suspected urinary tract infection. If the person is interested in participating in the study, then he/she will be given a leaflet with information about the study. This leaflet can be read while waiting for the consultation.
If the patient has further questions, they will be answered during the consultation to guarantee privacy. The patient is welcome to have a companion, in case they consider it is necessary in order to make a well-informed and thorough decision. However, due to the fact that these symptoms are acute and non-life-threatening complaints, in every day practice the patient uses to come alone. It means, to guarantee that the patient makes a non-influenced decision, the personnel is instructed to emphasize to the patients that they have as much time as the want to think about, they can ask questions and they can be sure that they refusal to participating in the project won't change the normal diagnostic process and treatment.
- Conditions
- Urinary Tract Infections
- Being tested
- Diagnostic approaches
- Medical subject headings
- Urinary Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diagnostic approachesOther
Also called Stix, microscopy, culture
General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of patients with appropriate antibiotic treatment decisions for each diagnostic approach during the consultation.
We will compare appropriate use of antibiotics within the different diagnostic approaches
Measured: 8 months
Secondary outcomes (3)
Number of days until clinical cure.
Number of days until clinical cure (i.e. first day without urinary symptoms)and number of days to become symptoms free.
Measured: 8 months
Number of days until microbiological cure.
Number of days until microbiological cure (i.e. culture reported as negative).
Measured: 8 months
Prevalence of resistant strains
Sensibility test
Measured: 8 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2014 (estimated)
- Study startDec 2014
- Primary completionDec 2015
- Study completionDec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Urinary Tract InfectionsStudies of the same condition, open and under way.
- More trials run by University of CopenhagenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gloria Cristina Cordoba, University of Copenhagen
- Investigators
- Lars Bjerrum, Professor, Study director, Department of general practice, University of Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02249273
- Sponsor's protocol ID
- UC-CARE-001
- Status last verified
- Oct 2017
- First submitted
- 22 Sep 2014
- Last updated
- 9 Oct 2017
- Results posted
- No
- Data monitoring committee
- No
Publications
Cordoba G, Holm A, Sorensen TM, Siersma V, Sandholdt H, Makela M, Frimodt-Moller N, Bjerrum L. Use of diagnostic tests and the appropriateness of the treatment decision in patients with suspected urinary tract infection in primary care in Denmark - observational study. BMC Fam Pract. 2018 May 16;19(1):65. doi: 10.1186/s12875-018-0754-1.
PubMed 29769025Cordoba G, Holm A, Hansen F, Hammerum AM, Bjerrum L. Prevalence of antimicrobial resistant Escherichia coli from patients with suspected urinary tract infection in primary care, Denmark. BMC Infect Dis. 2017 Oct 10;17(1):670. doi: 10.1186/s12879-017-2785-y.
PubMed 29017466Cordoba G, Sorensen TM, Holm A, Bjornvad CR, Bjerrum L, Jessen LR. Exploring the feasibility and synergistic value of the One Health approach in clinical research: protocol for a prospective observational study of diagnostic pathways in human and canine patients with suspected urinary tract infection. Pilot Feasibility Stud. 2015 Nov 10;1:38. doi: 10.1186/s40814-015-0036-9. eCollection 2015.
PubMed 27965816
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnostic Process in Patients With a Suspected Urinary Trcat Infection in Danish Primary Care: Impact on Appropriate Use of Antibiotics and Patient's Recovery.
- ClinicalTrials.gov ID
- NCT02249273
- Acronym / sponsor ID
- UC-CARE-001
- Conditions
- Urinary Tract Infections
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 500 participants (actual)
- Lead sponsor
- University of CopenhagenUniversity, hospital or other
- Study start
- Dec 2014
- Primary completion
- Dec 2015 (actual)
- Study completion
- Dec 2015 (actual)
- First posted
- 25 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Inappropriate use of antibiotics is one of the main causes for the increase of antibiotic resistance strains. In Denmark general practice accounts for 90% of all prescribed antibiotics and one of the most common reasons for prescribing antibiotics is the suspicion of a urinary tract infection (UTI). The use of point-of-care test is meant to decrease the uncertainty about the bacterial origin of the symptoms; however, there is a paucity of knowledge about the validity of the different diagnostic approaches, thus impacting on the proper use of antibiotics.
Objective: To assess the diagnostic validity of different diagnostic approaches in patients with a suspected urinary tract infection and assess the impact on appropriate use of antibiotics.
Methods: 70 practices at the capital region will consecutively include 15-20 patients. The inclusion criteria of the patients comprise: a) Suspected Urinary tract infection, b) > 18 years of age, c) patient consulting during office hours. Data at patient and GP level will be gathered.
16 diagnostic approaches will be compared and proper use of antibiotics will be assessed as a two-step process. The first step is the decision made during the consultation and the second step is the decision made after the consultation. Sensitivity, specificity and predictive values will be measure for each diagnostic approach using urine culture as a gold standard. The impact on proper use of antibiotics will be assessed in a hierarchical multivariable logistic model.
Detailed description
Background
The latest report from the Staten Serum Institute (SSI)1 showed that primary health care in Denmark represents 90% of all prescribed defined daily dose(DDD) of antibiotics, and that a growing consumption of antibiotics is running alongside increasing resistance to E. coli, specifically ESBL-producing E. coli (Extended Spectrum Beta Lactamase Producing E. coli) .
The main cause of E. coli infection at primary care level is a Urinary Tract Infection (UTI) which is one of the most frequent reasons for consultation in general practice in Denmark. Interestingly, there is no consensus yet about the most effective diagnostic approach to identify those patients that will benefit from antibiotic therapy.
Currently in Denmark, a wide variety of diagnostic approaches can be identified in primary care settings (i.e. only history taking, dipsticks, microscopy, culture and susceptibility testing in practice). Nonetheless, there is not conclusive evidence yet about the diagnostic validity of all these approaches and the association with appropriate prescription of antibiotics(i.e. correct decision to prescribe and correct choice of antibiotics reflecting the bacterial cause and resistance) and impact on patients' clinical and microbiological cure.
For example, some studies that only include uncomplicated UTIs have shown that symptoms alone have a very low predictive value leading to overuse of antibiotics2,3. However, Richards et al after comparing the response to antibiotics of women with symptoms of UTI and a negative dipstick test result, concluded that empirical antibiotic use guided only by symptoms was a reasonable option4.
Furthermore, microscopy and more recent diagnostic tools such as a culture performed in primary care settings have not been included in the latest pragmatic validation studies5,6. Phase-contrast microscopy is widely used in primary care in Denmark, although the very few studies on the subject show wide variation in sensitivity (60-100%) and specificity (49-100%) of urine microscopy to predict significant bacteriuria.
Besides susceptibility testing at primary care level is only done in Denmark and the quality control of the performance of these tests differs across the country. MIKAP (the Danish agency in charge of the surveillance of the quality of the microbiological tests performed in general practices) supervises only some Danish Regions and has not authority on the quality control of the tests carried out in the capital region.
In order to curb the development of resistance bacteria strains in patients with urinary tract symptoms and infections, we need to increase our knowledge of the validity of the different diagnostic approaches and its impact on proper use of antibiotics and recovery across the heterogeneous group of patients seeking health care in primary care.
Objectives
The central research question will be answered throughout the following specific objectives:
- To assess the diagnostic validity (i.e. sensitivity and specificity, positive and negative predictive value) of different diagnostic approaches in ruling in or ruling out a UTI in different sub-population groups in general practice.
- To describe the impact of different diagnostic approaches on the appropriateness of antibiotic therapy (i.e. decision to prescribe and choice of antibiotic).
- To describe the impact of different diagnostic approaches on clinical and microbiological cure.
- To measure the prevalence of ESBL-resistant E.coli in patients with urinary tract symptoms in general practice.
Materials and Methods:
Design and setting: Prospective observational study with comparison of different diagnostic approaches to gold standard in general practice.
Data Collection: Before the index consultation, the participating GPs will be asked to complete a background questionnaire about experience, organization of the service and access to different diagnostic tools.
The day of the index consultation, when the GP types the ICPC code for dysuria (U01) or frequency (U02), as a main motive of consultation, a pop-up will automatically appear with a questionnaire about the anamnesis, diagnostic approach, treatment and other relevant decisions made during the consultation; this questionnaire will be directly linked to DAK-E/DAMD database (Danish General Practice database aimed at improving quality in the delivery of primary medical care services). Afterwards, the patient will also be asked to provide a urine sample which will be sent to the Staten's Serum Institute (SSI) for culture, which will be used as the reference gold standard.
The following 14 days after the index consultation, the patients will complete a symptom diary (attached). They will be asked to rate some symptoms each day until recovery (or for 7 days if symptoms are ongoing) on a 3 point scale from "nothing " to "a lot". After 14 days patients will have to send a control urine sample. Patients with a persistently positive culture will be followed up after 1and 3 months.
Further information about patient background regarding co-morbidities, previous hospitalizations, and previous use of antibiotics will be gathered from national registers such as The Danish national patients register and The Danish national prescription register.
Biobank: 10 µl of urine will be stored following the safety and hygiene procedures of the Staten's Serum Institute microbiological laboratory only for those urine samples positive for ESBL-producing E. coli. After detection of a positive resistant strain, the samples will be anonymized and stored for a period of 2 years after completion of the current study. We plan to carry out further microbiological analysis of the resistant bacteria in collaboration with experts in proteonomics and genomics within the bigger UC-CARE projects. The collection of the urine sample does not represent any risk for the patients as it follows the normal procedure in general practice, it means, the patients is requested to collect a random urine sample in a plastic cup at the practice facility and 14 days after at home.
Data management: All data will be entered into a database which will be linked to different national registers to obtain detailed data about background information at patient level. Data will be screened for data entry errors and extreme values using tables, plots and specific commands of the SAS 9.03.
Variables: considering the multidimensional and multivariable models that will have to be constructed in order to accurately answer the objectives, the following variables with the corresponding data source will be included:
Patient level
Patients' demographics (gender, age), dysuria, frequency, supra-pubic pressure, polyuria, Fever (>38oC), trembling, urine offensive smell, gynecological complaints (vaginal discharge, pruritus), low back pain, blood in urine. Number of days since first symptom started. Diagnostic test:, diagnose, treatment, severity of symptoms, bothersomeness, impact on daily activities. Previous hospitalization within the last year: diagnosis, discharge date. Consumption of antibiotics within the last year.
GP level Number of consultations during office hours due to dysuria and/or frequency as a main motive of consultation, GPs' demographics, number of patients in the GPs' list, point-of-care test for urine examination: type of point-of-care tests available in the practice, brand and technical specifications for each test. Attendance to courses about performance of the tests.
Statistical analysis: Data will be analyzed using SAS 9.03. A comparison of proportions will be performed using the chi-square test. For the first two objectives, the result of the urine culture will be used as the gold standard, a cut-off value of >=103cfu/ml, or pure growth of E.coli, and > 10 4 for more unusual organisms or mixed growth will be used to define a positive culture,and we will calculate sensitivity, specificity, negative predictive value and positive predictive value for each diagnostic approach against the gold standard.
Regarding the third objective prescription of antibiotics and choice of the right antibiotic will be operationalized as binary dependent variables in a logistic regression model, while for the last two objectives number of days until symptomatic and microbiological cure will be analyzed as continuous dependent variables in a multiple linear regression model. Depending on the number of cases included in the one month and three months follow-up of microbiological cure, a Poisson regression model will be developed.
The propensity score matching technic will be employed to adjust for pre-test imbalances in the different groups of treatment approaches in order to produce unbiased estimates of the tests effect on the main outcomes and create participant characteristic balance among the groups.
Sample calculation Different samples sizes will be needed to compare proper use of antibiotics between the 16 diagnostic profiles. Due to the observational design of the study, we do not know yet with certainty the distribution of the diagnostic profiles, so at least there are two samples sized we are aiming at. The first one aims to see a clinically relevant 10% difference in proper use of antibiotics when comparing the diagnostic profiles that affect the decision during the consultation versus the diagnostic profiles that affect the decision after the consultation.
The assumptions are: a) the 4 diagnostic profiles that influence the decision during the consultation are use in 60% of the patients, b) the correct decision is taken in 60% of the patients in this group, while c) the correct decision during the consultation is taken only in 40% of the patients in which any of the remaining 12 diagnostic profiles are performed. We will need 60 practices recruiting 15 patients each (n=900). Intra-class correlation =0.2, α=0.05 and β=0.2.
The second sample size relates to the detection of a prevalence of ESBL-producing E. Coli between 0 to 6% in patients with a suspected UTI in primary care. Our assumptions for the sample calculation are as follows: a) 60% of patients with symptoms do not have a positive culture, b) 80% of the patients with a positive culture are infected with a E.Coli strain. Therefore, we need 1500 patients with a suspected UTI attending primary care to detect a prevalence of ESBL-resistant E.coli between 0 to 6% with a 95% confidence interval.
Ethics
The study does not represent any risk for the patients due to the observational design. It means the diagnostic process and the treatment will be register as it is done in every day practice. Participation in the study implies for the patient that they have to fill in a diary about symptoms for 7 days and they should be willing to be contacted 3 days and 14 days after by the personnel from the practice to know whether they have filled in the diary, sent it to the research unit and sent the second sample to the microbiological department. Consequently, the course of the symptoms/disease is not affected by the fact of participating or not in the study.
All the personnel at each practice will be informed about the study, so as soon as the patient contacts the practice due to the symptoms listed at the inclusion criteria section, they will receive the first information about the study.
The first contact person (i.e. secretary, nurse, general practitioner) will ask the patient whether they are interested in participating in a project that aims to improve the management of patients with a suspected urinary tract infection. If the person is interested in participating in the study, then he/she will be given a leaflet with information about the study. This leaflet can be read while waiting for the consultation.
If the patient has further questions, they will be answered during the consultation to guarantee privacy. The patient is welcome to have a companion, in case they consider it is necessary in order to make a well-informed and thorough decision. However, due to the fact that these symptoms are acute and non-life-threatening complaints, in every day practice the patient uses to come alone. It means, to guarantee that the patient makes a non-influenced decision, the personnel is instructed to emphasize to the patients that they have as much time as the want to think about, they can ask questions and they can be sure that they refusal to participating in the project won't change the normal diagnostic process and treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients >0 18 years old attending primary care services during offcie hours with a suspected urinary tract infection
Key inclusion criteria (3 listed)
- Suspected Urinary tract infection
- > 18 years of age
- Patient consulting during office hours.
Key exclusion criteria (3 listed)
- Patients currently taking antibiotics
- Inability to complete a diary and send two urine samples during the time of the study
- Patients with a urinary catheter as they have a closer follow-up between first and secondary care.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diagnostic approachesAlso: Stix, microscopy, cultureGeneral practitioners will register the diagnostic process in patients with a suspected urinary tract infection | Other | – |
Primary outcome
Percentage of patients with appropriate antibiotic treatment decisions for each diagnostic approach during the consultation.
Time frame: 8 months
We will compare appropriate use of antibiotics within the different diagnostic approaches
3 secondary outcomes
Number of days until clinical cure.
Time frame: 8 months
Number of days until microbiological cure.
Time frame: 8 months
Prevalence of resistant strains
Time frame: 8 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2017.
- Derived from this study: PubMed 29769025Cordoba G, Holm A, Sorensen TM, Siersma V, Sandholdt H, Makela M, Frimodt-Moller N, Bjerrum L. Use of diagnostic tests and the appropriateness of the treatment decision in patients with suspected urinary tract infection in primary care in Denmark - observational study. BMC Fam Pract. 2018 May 16;19(1):65. doi: 10.1186/s12875-018-0754-1.
- Derived from this study: PubMed 29017466Cordoba G, Holm A, Hansen F, Hammerum AM, Bjerrum L. Prevalence of antimicrobial resistant Escherichia coli from patients with suspected urinary tract infection in primary care, Denmark. BMC Infect Dis. 2017 Oct 10;17(1):670. doi: 10.1186/s12879-017-2785-y.
- Derived from this study: PubMed 27965816Cordoba G, Sorensen TM, Holm A, Bjornvad CR, Bjerrum L, Jessen LR. Exploring the feasibility and synergistic value of the One Health approach in clinical research: protocol for a prospective observational study of diagnostic pathways in human and canine patients with suspected urinary tract infection. Pilot Feasibility Stud. 2015 Nov 10;1:38. doi: 10.1186/s40814-015-0036-9. eCollection 2015.
- University of Copenhagen research center for control of antibiotic resistanceLink provided by the sponsor.
Related trials for Urinary Tract Infections
Recruiting
Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture
Urinary Tract Infections
Active, not recruitingObservational study
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
Complicated Urinary Tract Infection
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Recruiting
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS
Drug Resistance, Microbial, Biomarkers
Not yet recruitingObservational study
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
Urinary Tract Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lars Bjerrum, Professor study director
Department of general practice, University of Copenhagen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Urinary Tract Infections, run by University of Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of patients with appropriate antibiotic treatment decisions for each diagnostic approach during the consultation. (time frame: 8 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02249273, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2017.